Literature DB >> 22863827

Recognizing serotonin toxicity in the pediatric emergency department.

Shruti Kant1, Erica Liebelt.   

Abstract

The use of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in treating depression, mood disorders, and behavioral disorders has escalated dramatically in the last 20 years, resulting in increased risk and clinical presentation of serotonin toxicity. Health care providers must also be aware of other medications and substances with proserotonergic activity that can cause serotonin toxicity when used in combination with these medications. There are many adverse effects of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, although their toxicity profile compared to older antidepressants seems to be safer. Serotonin syndrome is described as a clinical triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. It encompasses a spectrum of clinical findings ranging from a few nonspecific symptoms to significant clinical toxicity that can result in death. The objectives of this article are to review specific serotonergic medications including their adverse effects and toxicity in overdose, to describe other medications/substances that have proserotonergic effects, which could result in serotonin excess in combination with traditional serotonergic agents, and to define the criteria for serotonin syndrome/toxicity and its treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863827     DOI: 10.1097/PEC.0b013e31826289d9

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  5 in total

1.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

2.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

3.  SSRIs-Related Behavioural Syndromes in Children and Adolescents.

Authors:  Ahmed Naguy
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-05-01

Review 4.  Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome.

Authors:  Gabrielle L McLemore; Tamorah Lewis; Catherine H Jones; Estelle B Gauda
Journal:  Semin Fetal Neonatal Med       Date:  2012-10-09       Impact factor: 3.926

5.  Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Stephan Schmidt; Ai-Ming Yu
Journal:  Acta Pharm Sin B       Date:  2016-08-06       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.